Education
About Us
Working with TipRanks
Follow Us
Transgene SA (FR:TNG)
:TNG
Top Page
Transgene
(TNG)
Select Model
Select Model
Rating:43Neutral
Price Target:
€0.88
▼(-5.96% Downside)
Transgene's overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including a drastic revenue decline and high operational losses. Technical indicators show bearish momentum, with the stock trading below key moving averages and approaching oversold conditions. Valuation metrics further highlight the company's unprofitability, contributing to a low overall score.
Positive Factors
Strong Phase I Results for TG4050
The positive Phase I results for TG4050 demonstrate the potential efficacy of Transgene's immunotherapy approach, supporting long-term growth prospects in the oncology market.
Financial Stability Until 2026
Securing financial stability until 2026 provides Transgene with the runway to advance its R&D initiatives without immediate capital constraints, enhancing its strategic execution.
Strategic Focus on myvac Platform
Focusing on the myvac platform aligns Transgene's resources with high-value opportunities, potentially capturing significant market share in personalized cancer vaccines.
Negative Factors
Significant Revenue Decline
The drastic revenue decline highlights challenges in monetizing its pipeline, which could impact long-term financial sustainability and operational funding.
Negative Cash Flow
Persistent negative cash flow indicates ongoing liquidity issues, which may constrain the company's ability to invest in growth and R&D without additional funding.
Uncertainty in Regulatory Pathway for TG4050
Regulatory uncertainty for TG4050 could delay commercialization, affecting revenue timelines and increasing the risk associated with the product's development.
Transgene (TNG) vs. iShares MSCI France ETF (EWQ)
Market Cap
€260.21M
Dividend YieldN/A
Average Volume (3M)129.86K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth111.76%
EPS Growth-22.45%
CountryFR
Employees144
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding274,186,700
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)5.22
Price to Sales (P/S)12.49
P/FCF Ratio-2.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Transgene Business Overview & Revenue Model
Company DescriptionTransgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
How the Company Makes MoneyTransgene generates revenue through various channels, including partnerships and collaborations with larger pharmaceutical companies that seek to leverage Transgene's innovative technologies for their own drug development. Additionally, the company may receive milestone payments and royalties from these collaborations upon the successful development and commercialization of therapeutic candidates. Another potential revenue stream includes the sale of its own therapeutic products, once they receive regulatory approval and are brought to market. Furthermore, Transgene may also engage in grants and funding from public and private entities to support its research and development initiatives, contributing to its overall financial health.
Transgene Earnings Call Summary
Earnings Call Date:Sep 16, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Mar 18, 2026
Earnings Call Sentiment Positive
The earnings call painted a positive picture for Transgene with strong Phase I results for TG4050 and financial stability secured until the end of 2026. However, challenges remain in the broader financing environment, and there is uncertainty about the regulatory pathway for TG4050.Q2-2025 Updates
Positive Updates
Promising Phase I Results for TG4050
All operable head and neck squamous cell carcinoma patients treated with TG4050 remain disease-free after a median follow-up of 30 months. Safety and immunogenicity endpoints were met, with durable immune responses observed.
Ongoing Progress in Phase II Trial
The Phase II trial for TG4050 in head and neck cancer is progressing well, with plans to randomize the last patient in Q4 2025. First immunogenicity data are expected in the second half of 2026.
Financial Stability Extended
The company's financial outlook has improved, with funding secured until the end of December 2026, thanks to a credit facility and support from TGH.
Strategic Focus on myvac Platform
The company is prioritizing its resources on the myvac platform and TG4050, which is expected to cater to a market of over $1 billion per year at peak.
Negative Updates
Challenges in Financing Environment
The overall financing environment for biotech companies remains challenging, necessitating a focus on key value-creating programs.
Uncertainty in Regulatory Pathway for TG4050
Further clarity on the regulatory pathway for TG4050 is not expected until Q2 2026, after discussions with clinicians and health authorities.
Limited Focus on Other Programs
Programs such as TG4001, TG6050, and BT-001 are not receiving the same level of focus due to prioritization of the myvac platform.
Company Guidance
During the Transgene 2025 Half Year Financial Results Conference Call, several key metrics and milestones were highlighted. The company presented 24-month disease-free survival data for Phase I patients treated with the Individualized Therapeutic Vaccine, TG4050, showing 100% survival at two years in operable head and neck squamous cell carcinoma patients. The Phase II trial is progressing well, with the last patient expected to be randomized in Q4 2025, and initial immunogenicity data anticipated in the second half of 2026. The two-year efficacy data is expected in Q4 2027. The company aims to expand the myvac platform into other early solid tumor settings and is preparing a new Phase I trial pending regulatory and financial conditions. Financially, Transgene is funded until December 2026, supported by a credit facility and engagement from TGH. These developments underscore the company's strategic focus on advancing its myvac platform and TG4050 amid a competitive landscape.Transgene Financial Statement Overview
Summary
Transgene is facing financial difficulties with significant revenue decline and high operational losses, as seen in the income statement. The company's balance sheet is stable due to zero debt, but the erosion of equity is concerning. Cash flow remains negative, highlighting ongoing liquidity challenges. Despite some positive aspects like zero debt, the overall financial health of Transgene is strained, requiring strategic adjustments to improve revenue streams and reduce losses.Income Statement
Transgene has shown a significant deterioration in revenue over the past year, with total revenue dropping from €7.9 million in 2023 to €307,000 in 2024. This represents a revenue decline of approximately 96%. The company is also experiencing negative profit margins, with a net profit margin of -11067% and an EBIT margin of -11616% for 2024, indicating substantial losses relative to its revenue. However, the gross profit margin is technically 100% due to a very small revenue base and the absence of cost of goods sold, which reflects poor revenue diversification and high operational losses.45
Neutral
Balance Sheet
The balance sheet indicates a relatively stable financial position with zero debt, resulting in a debt-to-equity ratio of 0. The equity ratio stands at 36%, which suggests a moderate level of equity financing. Return on equity (ROE) is deeply negative at -223% due to significant net losses. The absence of debt is a strength, reducing financial risk, but the persistent erosion of equity through losses poses a substantial concern.55
Neutral
Cash Flow
Transgene's cash flow situation is challenging, with a free cash flow of -€26.6 million in 2024 compared to -€37.4 million in 2023, indicating some improvement but still deeply negative. The operating cash flow to net income ratio is 0.69, reflecting a shortfall in cash generation relative to accounting losses. The free cash flow to net income ratio is negative, indicating continued cash burn despite some capital discipline.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.09M | 6.35M | 7.90M | 3.13M | 9.99M | 2.98M |
| Gross Profit | -15.86M | -27.93M | -21.69M | -29.04M | -22.89M | -24.36M |
| EBITDA | -40.48M | -26.65M | -28.44M | -30.33M | -23.55M | -14.13M |
| Net Income | -36.78M | -33.97M | -22.33M | -32.81M | -20.00M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 40.99M | 42.17M | 45.22M | 66.44M | 101.84M | 85.45M |
| Cash, Cash Equivalents and Short-Term Investments | 16.77M | 16.67M | 15.67M | 26.83M | 49.57M | 26.35M |
| Total Debt | 30.57M | 10.40M | 1.35M | 2.45M | 3.84M | 5.28M |
| Total Liabilities | 44.59M | 26.97M | 29.61M | 28.59M | 34.63M | 35.20M |
| Stockholders Equity | -3.60M | 15.20M | 15.61M | 37.84M | 67.21M | 50.25M |
Cash Flow | ||||||
| Free Cash Flow | -25.23M | -26.62M | -37.42M | -21.84M | -32.63M | -29.59M |
| Operating Cash Flow | -23.89M | -23.55M | -34.67M | -20.30M | -31.94M | -28.74M |
| Investing Cash Flow | -2.35M | -3.21M | 34.57M | 20.27M | 16.79M | 17.74M |
| Financing Cash Flow | 28.70M | 26.96M | 11.37M | -1.48M | 15.77M | 14.94M |
Transgene Technical Analysis
Negative
0.94
Price Trends
1.06
Negative
1.13
Negative
0.96
Negative
Market Momentum
-0.02
Negative
46.26
Neutral
44.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:TNG, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.06, and below the 200-day MA of 0.96, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.26 is Neutral, neither overbought nor oversold. The STOCH value of 44.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:TNG.
Transgene Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €262.89M | -6.76 | -51.06% | ― | -45.41% | -273.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €738.55M | -3.88 | -241.12% | ― | ― | 3.09% | |
49 Neutral | €894.17M | ― | ― | ― | ― | ― | |
49 Neutral | €107.71M | -3.03 | -52.76% | ― | -96.92% | -175.84% | |
47 Neutral | €141.12M | -2.74 | -271.32% | ― | -75.86% | -30.54% | |
43 Neutral | €260.21M | -3.41 | ― | ― | 111.76% | -22.45% |
* General Sector Average
FR:TNG
Transgene
0.95
0.25
34.94%
FR:GNFT
Genfit
5.27
1.78
51.29%
FR:IPH
Innate Pharma SA
1.51
-0.22
-12.75%
FR:DBV
DBV Technologies
3.68
2.76
300.00%
FR:NANO
Nanobiotix
18.48
15.44
507.89%
FR:OSE
OSE Immunotherapeutics SA
4.80
-1.75
-26.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.